Long term survivors and immune biomarker analysis of Phase IIa, randomized study of GVAX pancreas and crs-207 immunotherapy in patients with metastatic pancreatic cancer

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2015

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 11 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 27,870 followers.

RT @Aiims1742: #SITC15 #immunotherapy trial of $ADRO GVAX/CRS207 vaccine in metastatic #PancreaticCancer - 7/90 Pts alive >3 years https://…

Reply Repost Favourite

#SITC15 #immunotherapy trial of $ADRO GVAX/CRS207 vaccine in metastatic #PancreaticCancer - 7/90 Pts alive >3 years https://t.co/2MC5c3wW8s

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.